Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04843930 · ClinicalTrials.gov registry record · Phase 2
Improving Cognitive Health in COVID-19 Survivors
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT04843930 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 110 participants.
The verdict
NCT04843930, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the efficacy of AKL-T01, a remotely-delivered digital cognitive intervention, relative to a waitlist control in improving cognitive functioning in COVID-19 survivors.
Interventions
- DEVICE AKL-T01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2023-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04843930
The ClinicalTrials.gov registry entry for NCT04843930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AKL-T01 is the first listed.
NCT04843930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04843930 about?
NCT04843930 is a clinical study titled "Improving Cognitive Health in COVID-19 Survivors". The primary objective of this study is to investigate the efficacy of AKL-T01, a remotely-delivered digital cognitive intervention, relative to a waitlist control in improving cognitive functioning in COVID-19 survivors.
What is the current status of trial NCT04843930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2021-07-13. Estimated completion is 2023-04-26.
What interventions are being tested in trial NCT04843930?
The interventions under investigation include: AKL-T01 (DEVICE).
Who is sponsoring clinical trial NCT04843930?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.